<DOC>
	<DOCNO>NCT00004037</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness docetaxel treat patient recurrent refractory ovarian primary peritoneal cancer .</brief_summary>
	<brief_title>Docetaxel Treating Patients With Recurrent Refractory Ovarian Primary Peritoneal Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Estimate antitumor activity docetaxel patient paclitaxel- platinum-resistant , recurrent refractory , ovarian epithelial primary peritoneal cancer fail high priority treatment protocol . II . Determine nature degree toxicity docetaxel patient population . OUTLINE : Patients receive docetaxel 1 hour continuous intravenous infusion . Courses repeat every 21 day . Treatment continue absence unacceptable toxic effect disease progression . All patient follow every 3 month 2 year , every 6 month 3 year , death . PROJECTED ACCRUAL : A total 23-56 patient accrue study .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm recurrent refractory ovarian epithelial peritoneal cancer Platinum resistant AND paclitaxel resistant Progressed within 6 month complete therapy paclitaxel platinum either alone combination Bidimensionally measurable disease ( excludes ascites pleural effusion ) Brain metastasis allow provide measurable disease exist brain lesion require therapy 6 month life threaten Not eligible high priority GOG protocol PATIENT CHARACTERISTICS : Age : 18 Performance status : GOG 02 Life expectancy : At least 8 week Hematopoietic : WBC least 3,000/mm3 Platelet count least 100,000/mm3 Granulocyte count least 1,500/mm3 Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) SGOT/SGPT great 1.5 time ULN Alkaline phosphatase great 2.5 time ULN Renal : Creatinine great 2.0 mg/dL Other : No significant infection Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No history allergic reaction polysorbate 80 ( e.g. , etoposide vitamin E ) No invasive malignancy within past 5 year except nonmelanoma skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics Must least 1 prior platinum base chemotherapeutic regimen contain carboplatin , cisplatin , another organoplatinum compound Must least 1 prior paclitaxel base chemotherapeutic regimen 1 2 prior chemotherapy regimen contain platinum paclitaxel allow Recovered toxic effect No prior docetaxel Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy Surgery : Recovered effect recent surgery Other : At least 3 week since prior therapy direct malignant tumor No prior cancer treatment contraindicate protocol therapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2003</verification_date>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>primary peritoneal cavity cancer</keyword>
</DOC>